AAP
SPRY icon

Arax Advisory Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Arax Advisory Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$33.4K Buy
4,169
+3,825
+1,112% +$32.9K ﹤0.01% 3598
2026
Q1 		$2.76K Sell
344
-25
-7% -$240 ﹤0.01% 3008
2025
Q4 		$4.3K Buy
369
+241
+188% +$2.34K ﹤0.01% 2935
2025
Q3 		$1.29K Buy
+128
New +$1.84K ﹤0.01% 3202
2024
Q4 		– Sell
-22
Closed -$319 – 2728
2024
Q3 		$319 Hold
22
– – ﹤0.01% 2465
2024
Q2 		$188 Buy
+22
New +$195 ﹤0.01% 2446

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Arax Advisory Partners's SPRY Position: Q2 2026 in Review

Arax Advisory Partners increased its ARS Pharmaceuticals (SPRY) stake by 1,112% in Q2 2026, buying an estimated $32.9K and bringing the position to 4,169 shares worth $33.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3598.

Arax Advisory Partners first reported a position in SPRY in Q2 2024 and has held it in 6 quarters since. 206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Arax Advisory Partners held 4,169 shares of ARS Pharmaceuticals worth $33.4K as of Q2 2026.
  • Arax Advisory Partners bought 3,825 ARS Pharmaceuticals shares in Q2 2026, an estimated $32.9K.
  • ARS Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #3598 holding.
  • Arax Advisory Partners first reported a position in ARS Pharmaceuticals in Q2 2024 and has held it in 6 quarters since.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.